Rhythm is a late-stage biopharmaceutical company dedicated to changing how rare genetic disorders of obesity are diagnosed and treated. Disorders of severe obesity may result from genetic variants within the melanocortin-4 receptor (MC4R) pathway, a key pathway responsible for regulating weight, that lead to excessive or insatiable hunger or hyperphagia. Rhythm’s MC4R agonist, setmelanotide, is being evaluated in multiple late-stage clinical studies. The Company recently announced positive topline results from pivotal Phase 3 clinical trials of setmelanotide, its MC4R agonist, in people living with POMC deficiency obesity and LEPR deficiency obesity, and it plans to complete its first rolling NDA submission to the FDA in the first quarter of 2020. Rhythm completed enrollment in the pivotal cohort in its Phase 3 trial in people living with Bardet-Biedl and Alström syndromes, with topline data from this trial expected in the fourth quarter of 2020 or early in the first quarter of 2021.
Rhythm is leveraging the Rhythm Engine -- comprised of its Phase 2 basket study, TEMPO Registry, GO-ID genotyping study and Uncovering Rare Obesity program -- to improve the understanding, diagnosis and potentially the treatment of rare genetic disorders of obesity.
For healthcare professionals, visit www.UNcommonObesity.com for more information.
For patients and caregivers, visit www.LEADforRareObesity.com for more information.
The company is based in Boston, MA.